Tests allogeneic NK cells with rituximab and tafasitamab in lymphoma
Tests donor immune NK cells with antibody drugs in adults with returned B-cell lymphoma.
Key facts
- Who runs it
- Paolo Caimi, MD
- Where
- Cleveland, United StatesSee the 2 sites
- Trial code
- Registry title
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- Sept 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Allogeneic NK cells
- Rituximab
- Tafasitamab
- Interleukin-2
- Fludarabine/cyclophosphamide
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded after two or more earlier treatments. It tests NK cells given with rituximab, tafasitamab and IL-2.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- B-cell non-Hodgkin lymphoma (including DLBCL, high-grade B-cell lymphoma, PMBCL, follicular, CLL/SLL, marginal zone and mantle cell lymphoma) that has come back or not responded after two or more lines of treatment. The disease must be measurable on scans or blood tests. ECOG performance status 2 or lower.
- Earlier treatment
- Two or more earlier lines of systemic treatment, including earlier CD19 and/or CD20 directed therapy. At least 28 days must have passed since any investigational drug.
- Biomarker or test result
- If you had earlier CD19 or CD20 directed therapy, a biopsy taken after relapse must show CD19 and/or CD20 on the lymphoma cells.
Main reasons for not taking part
- A second active cancer that could confuse the results (some skin cancers and carcinoma in situ are allowed)
- Pregnant or breastfeeding women
- Heart failure NYHA class III-IV, or a heart attack, stroke or unstable angina within 6 months
- Active lymphoma in the brain or spinal fluid, or relevant brain disease such as epilepsy or dementia
- Active hepatitis B or C, or HIV that is not well controlled
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age 18 years or older
- Diagnosis of B-cell NHL (indolent and aggressive subtypes) including diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)
- Participants must have measurable disease as defined by Lugano 2014 criteria for NHL or iwCLL 2018 criteria for CLL. For NHL, measurable disease is defined as ≥1 measurable lesion (nodal or extra nodal) ≥1.5 cm in longest diameter by CT or PET/CT. For CLL, iwCLL criteria includes: presence of lymphocytosis (e.g., ALC ≥5 × 10⁹/L), lymphadenopathy ≥1.5 cm, and/or disease-related cytopenias (anemia, thrombocytopenia)
- Relapsed and/or refractory after two or more lines of systemic therapy, including prior CD19 and/or CD20 directed therapies
- For participants who have received a prior CD19 or CD20 directed therapy, the presence of CD19 and/or CD20 expression (by flow cytometry and/or immunohistochemistry) must be demonstrated on a post-treatment relapse biopsy
- ECOG Performance Status </= 2
- Preserved organ function as defined by: Total bilirubin </= 1.5X upper limit of normal; AST/ALT </= 2.5 X upper limit of normal; Calculated creatinine clearance >/= 30mL/min estimated by Cockcroft Gualt formula; cardiac ejection fraction >/= 45% and no more than mild/trace pericardial effusion on a recent echocardiogram; and adequate pulmonary function with oxygen saturation >/= 92% on room air
- Participants must have the ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Less than 28 days elapsed between prior treatment with investigational agent(s) and study enrollment
- Cardiovascular disorders including unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event) within 6 months prior to registration
- Morphologic and/or cytogenetic features consistent with diagnosis of myelodysplastic syndrome on the most recent bone marrow biopsy prior to initiation of therapy
- Serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive participants will be excluded)
- Active central nervous system or leptomeningeal involvement by lymphoma. Participants with untreated brain metastases/CNS disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurological and other adverse events. Participants with a history of CNS or meningeal involvement must be in a documented remission by CSF evaluation and contrast enhanced MRI imaging for at least 90 days prior to registration
- Second active malignancy (other than non-melanoma skin cancer or carcinoma in situ e.g. cervix, bladder, breast) that would confound interpretation of toxicity assessment or limit survival to prevent evaluation of therapy per discretion of principal investigator. Malignancies treated curatively or with hormonal therapy could be included after discussion with the principal investigator
- New York Heart Association class III-IV congestive heart failure
- Known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness, except well controlled HIV with viral load <200 copies/mL on antiretroviral therapy
- Participants with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease
- History of active autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of systemic immunosuppressive medications other than low dose steroids [i.e. maximum of 15mg prednisone equivalent] within the last 6 months
- Pregnant or breastfeeding women are excluded from this study because therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants' secondary to treatment of the mother with NK cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study
Where in United States
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer InstituteCleveland, United StatesContact: Paolo Caimi, MDTaking people
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer CenterCleveland, United StatesContact: Changchun (George) DengNot yet recruiting
About the trial
What the trial wants to find out
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
Read full original descriptionShow less
NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death).
Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
The group in the trial
- Rtx + Tafasitamab in combination with allogeneic NK CellsTreatment being tested
This arm includes dose escalation for allogeneic NK cells. All other therapies are given according to standard of care. The length of the treatment period is 28 days per cycle. Participants will be expected to complete one cycle and may have the option to complete a second cycle unless there is evidence of disease progression at the end of the first cycle.
Treatment: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, and Fludarabine/cyclophosphamide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma
- Plain-language title
- Tests allogeneic NK cells with rituximab and tafasitamab in lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 September 2026